Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29053759 | 0.98 | MAPT (0.68) | MAPTALDH1A1GAAMPOCYP1A2 | |
| SCHEMBL4092371 | 0.92 | ALDH1A1 (0.75) | MAPTALDH1A1GAAMPOCYP1A2 | |
| SCHEMBL2378991 | 0.90 | ALDH1A1 (0.69) | MAPTALDH1A1GAAMPOCYP1A2 | |
| SCHEMBL2379635 | 0.89 | ALDH1A1 (0.67) | MAPTALDH1A1GAAMPOCYP1A2 | |
| Indolylpropionic Acid SCHEMBL4973575 | 0.85 | ALDH1A1 (0.71) | MAPTALDH1A1GAAMPOCYP1A2 | |
| Indolylpropionic Acid SCHEMBL29521227 | 0.85 | MAPT (0.68) | MAPTALDH1A1GAAMPOCYP1A2 | |
| Indolylpropionic Acid SCHEMBL29374161 | 0.85 | MAPT (0.68) | MAPTALDH1A1GAAMPOCYP1A2 | |
| SCHEMBL28378507 | 0.85 | MAPT (0.68) | MAPTALDH1A1GAAMPOCYP1A2 | |
| Indolylpropionic Acid SCHEMBL195405 | 0.85 | MAPT (0.68) | MAPTALDH1A1GAAMPOCYP1A2 | |
| Tryptamine SCHEMBL16990205 | 0.84 | HTR2C (0.78) | MAPTALDH1A1GAAMPOCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-119095964-A | Multi-tail and multi-cap mRNA and uses thereof | 博德研究所 | 2024-12-06 | — | — | CN | claimed |
| CN-118076741-A | Modified mRNA, modified non-coding RNA and uses thereof | 布罗德研究所股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-116440126-A | Application of 1H-indole-3-propionamide sodium channel regulator | 浙江大学 | 2023-07-18 | — | — | CN | claimed |
| CN-116286830-A | Aptamer | 中国人民解放军军事科学院军事医学研究院 | 2023-06-23 | — | — | CN | claimed |
| CN-115151263-A | Aptamers and uses thereof | 爱普济德生物技术有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-1957454-B1 | METHODS FOR SYNTHESIS OF 3-AMINO-1-ARYLPROPYL INDOLES | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | claimed |
| JP-2002537300-A | — | — | 2002-11-05 | — | — | JP | claimed |
| WO-2002048099-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GMBH (DE) | 2002-06-20 | — | — | WO | claimed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | claimed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | claimed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | claimed |
| EP-0669830-A4 | SUBSTITUTED DIPEPTIDE ANALOGS PROMOTE RELEASE OF GROWTH HORMONE. | MERCK & CO INC (US) | 1997-02-26 | — | — | EP | claimed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | claimed |
| EP-0669830-A1 | SUBSTITUTED DIPEPTIDE ANALOGS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1995-09-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | MAPT 2815/4885ALDH1A1 4801/4885GAA 4129/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | MAPT 3379/4885ALDH1A1 4742/4885GAA 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.